CAJ | 학술논문

目的探讨三磷酸腺苷生物荧光法(ATP-TCA)体外药敏试验在复发或难治非霍奇金淋巴瘤( NHL)治疗中的临床应用价值.方法应用ATP-TCA技术对复发或耐药淋巴瘤患者术后新鲜组织标本共34例进行体外药敏试验,观察用敏感药物化疗疗效.结果淋巴瘤标本的药物敏感性具有个体差异性,不同化疗药物的体外抑瘤活性不同.药敏试验组总有效率(RR)为82.4％(28/34),完全缓解(CR)率为52.9％(18/34)；DICE化疗组RR为60.0％( 18/30),CR率为33.3％(10/30)；GDP化疗组RR为62.3％(33/53),CR率为26.4％(14/53).药敏试验组的RR与DICE组及GDP组相比,差异有统计学意义(x2=3.93,P=0.047; x2=3.98,P=0.046).结论 ATP-TCA体外药敏检测结果与临床治疗反应有很好的相关性,是开展肿瘤个体化化疗的一种重要的体外药物筛选方法.
목적 탐토삼린산선감생물형광법(ATP-TCA)체외약민시험재복발혹난치비곽기금림파류( NHL)치료중적림상응용개치.방법 응용ATP-TCA기술대복발혹내약림파류환자술후신선조직표본공34례진행체외약민시험,관찰용민감약물화료료효.결과 림파류표본적약물민감성구유개체차이성,불동화료약물적체외억류활성불동.약민시험조총유효솔(RR)위82.4％(28/34),완전완해(CR)솔위52.9％(18/34)；DICE화료조RR위60.0％( 18/30),CR솔위33.3％(10/30)；GDP화료조RR위62.3％(33/53),CR솔위26.4％(14/53).약민시험조적RR여DICE조급GDP조상비,차이유통계학의의(x2=3.93,P=0.047; x2=3.98,P=0.046).결론 ATP-TCA체외약민검측결과여림상치료반응유흔호적상관성,시개전종류개체화화료적일충중요적체외약물사선방법.
Objective To investigate the clinical value of ATP bioluminescence tumor chemosensitivity assay (ATP-TCA) for recurrent and refractory non-Hodgkin lymphoma (NHL) specimens in vitro.Methods Thirty-four freshly taken recurrent and refractory NHL specimens were tested in vitro for cancer chemosensitivity by ATP-TCA.Results Drug sensitivity of NHL specimens had heterogeneity.Different drugs had different tumor growth inhibition ratio in vitro.Response rate (RR) of the patients receiving chemotherapy according to in vitro assay was 82.4 ％ (28/34),complete response rate (CR) was 52.9 ％ (18/34).In DICE group RR was 60.0 ％ (18/30),CR rate was 33.3 ％ (10/30).In GDP group RR was 62.3 ％ (33/53),CR rate was 26.4 ％ (14/53).In ATP-TCA group RR was significantly higher than those in DICE and GDP groups (x2 =3.93,P =0.047; x2 =3.98,P =0.046).Conclusion The results of ATP-TCA assay are correlated well with clinical treatment responses.The assay may be an important and useful method for individual-based chemotherapy of cancers.